The Latent Tuberculosis Infection Detection Market Size is valued at USD 1.53 billion in 2023 and is predicted to reach USD 2.37 billion by the year 2031 at a 5.7% CAGR during the forecast period for 2024-2031.
Latent tuberculosis infection (LTBI) detection is a critical component of tuberculosis (TB) control, aiming to prevent the progression to active TB disease. Regular screening and effective detection strategies are vital for reducing TB incidence and controlling outbreaks. The latent tuberculosis infection detection market is experiencing growth due to the rising prevalence of tuberculosis worldwide. Various diagnostic methods, such as tuberculin skin tests, interferon-gamma release assays, and molecular tests, are used to detect latent tuberculosis infection. Factors driving market growth include increased awareness, government initiatives for tuberculosis control, and advancements in diagnostic technologies. Key market players are funding for research and development to introduce innovative detection methods.
The market is expected to continue expanding as healthcare systems focus on early detection and treatment of latent tuberculosis to prevent its progression to active disease. The rising risk of developing active disease from latent tuberculosis infection is one of the major driving factors for market growth. In addition, rising awareness about TB detection and various government initiatives for effective diagnosis and screening of tuberculosis infection are other factors contributing to market expansion.
The latent tuberculosis infection detection market segmentation includes segments based on Brand, Test Type, Application, and End-Use. As per the brand segment, the market consists of QFT-Plus (QuantiFERON-TB Gold Plus and Others. Based on Test Type, the market segments include Tuberculin Skin Test (TST) and Interferon Gamma Release Assay (IGRA). Based on Application, the market segments are Household Contacts with Pulmonary TB, PLHIV, and Others. Based on End-users, the market is segmented as Diagnostic Laboratories, Hospitals/Clinics, and Academic & Research Institutions.
The Hospitals/Clinics segment plays a vital role in the latent tuberculosis infection (LTBI) detection market. These healthcare settings are primary locations for diagnosing and managing LTBI due to their access to advanced diagnostic tools and specialized healthcare professionals. Hospitals and clinics conduct screening using methods like the Tuberculin Skin Test (TST) and Interferon-Gamma Release Assays (IGRAs). The growth of this segment is due to the rising prevalence of TB, increasing government and non-government initiatives for TB control, and the emphasis on early detection and treatment. Additionally, hospitals and clinics serve as key centres for implementing TB screening programs, especially in high-risk populations.
The tuberculin skin test (TST) segment is a crucial part of the detection market for latent tuberculosis infection (LTBI). It is widely used due to its simplicity, low cost, and established use in clinical practice. Despite its limitations, such as cross-reactivity with BCG vaccination and non-tuberculous mycobacteria, TST remains a standard screening tool, especially in resource-limited settings. The segment is driven by the ongoing need for TB control, government screening programs, and efforts to identify and treat LTBI in high-risk populations.
The North American latent tuberculosis infection detection market is projected to obtain the maximum market share. The opportunities in the form of unmet medical needs, scientific research, and economic growth are some primary growth drivers of this market. The rise of the healthcare regulatory scenario in countries is estimated to attract international players to capitalize and invest in existing opportunities. Asia Pacific is to be seen to grow at a rapid rate in the global latent tuberculosis infection detection market industries due to growing concerns about government initiatives and increasing funding in various ways.
| Report Attribute | Specifications |
| Market Size Value In 2023 | USD 1.53 Bn |
| Revenue Forecast In 2031 | USD 2.37 Bn |
| Growth Rate CAGR | CAGR of 5.7% from 2024 to 2031 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
| Historic Year | 2019 to 2023 |
| Forecast Year | 2024-2031 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Brand, Test Type, Application, End-Use |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
| Competitive Landscape | Wantai BioPharm, Lionex GmbH, QIAGEN, BIOMÉRIEUX, Oxford Immunotec, SD Biosensor INC., Sanofi, Serum Institute of India Pvt. Ltd, ARKRAY, Inc., Par Pharmaceutical, Inc., and others |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Latent Tuberculosis Infection Detection Market By Test Type –
Latent Tuberculosis Infection Detection Market By Application –
Latent Tuberculosis Infection Detection Market By End-user –
Latent Tuberculosis Infection Detection Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.